About DePuy Synthes

  • Contact Us
  • Healthcare Providers

Search DePuy Synthes


News and Press

DePuy Synthes EMEA Launches ATTUNE Revision Knee System to Deliver Stability in Motion for More Patients

Comprehensive revision system designed to address broad range of Complex Primary and Revision procedures

31 May 2018, Barcelona, SPAIN 
– DePuy Synthes*, part of the Johnson & Johnson Medical Devices Companies**, today announced the Europe, Middle East and Africa launch of the ATTUNE Revision Knee System, to complement the ATTUNE Primary Knee System and provide surgeons with a comprehensive solution for knee replacement. The ATTUNE Revision Knee System is being unveiled at the 19th European Federation of the National Associations of Orthopaedics and Traumatology (EFORT) Congress, taking place in Barcelona, Spain.

While knee replacement is widely recognized as one of the most common and successful surgical procedures, according to registry data, approximately six percent of patients will require a revision surgery 10 years after the initial procedure.1 Revision surgeries are regarded as complex, particularly in cases where large bone defects present reconstruction and fixation challenges. The ATTUNE Revision Knee System aims to address some of those challenges through improved kinematics, fixation and patient fit. With both fixed-bearing and rotating platform options, it is one of the most comprehensive revision knee systems available on the market today.

“The ATTUNE Revision Knee System is a step forward for patients - the System feels like a primary total knee intraoperatively and patients experience a smooth range of motion,”
said Mr Peter James***, Consultant Orthopaedic Surgeon, Nottingham City Hospital. “From a clinical perspective, the benefit of using the same system for primary and revision knee replacement procedures provides greater options for complex primary procedures and can lead to a smoother learning curve for surgeons and the wider hospital team.”

The ATTUNE Revision Knee System is designed to work in harmony with the patient’s anatomy to deliver stability in motion during activities such as stair ascent or descent, walking uphill or downhill or getting up from a chair through:

– ATTUNE GRADIUS Curve, designed to address the unnatural sliding of the femur on the tibia, to provide smooth motion and stability during everyday activities
– GLIDERIGHT® Articulation, designed to enable the ATTUNE Knee design to more accurately replicate the normal patello-femoral kinematics of the native knee

“With the addition of the ATTUNE Revision Knee to our existing ATTUNE Knee System platform, we hope to be able to continue to improve knee replacements satisfaction rates for more patients across Europe, the Middle East and Africa,” said Torbjorn Skold, Vice President, DePuy Synthes EMEA Joint Reconstruction.

DePuy Synthes is committed to the continued evaluation of outcomes of the ATTUNE Knee System through its comprehensive ATTUNE Knee Evidence Generation Program that gathers information from national joint registries, investigator-initiated studies, independent studies and company initiated studies. Recent findings from a multicenter study of 200 cases from The Netherlands found that the ATTUNE Primary Knee System showed a statistically significant improvement in knee physical function at six months compared to preoperative baseline, using the Knee injury and Osteoarthritis Outcome Score- Physical Function Short Form (KOOS-PS). In addition, 80 percent of those ATTUNE Knee patients’ KOOS-PS improvements were realized by six months, with statistically significant improvements observed at intervals prior to six months. Also, pain and other PROMS were statistically significantly better at six weeks compared with pre-operative baseline.2 The same technologies that helped deliver these outcomes are also incorporated in the ATTUNE Revision Knee System, helping to address overall patient satisfaction.

For more information relating to the ATTUNE Knee, please click here .

About the Johnson & Johnson Medical Devices Companies
The Johnson & Johnson Medical Devices Companies** have been working to make surgery better for more than a century. With substantial breadth and depth in surgical and orthopaedic technologies and interventional solutions, we aspire to improve and enhance medical care for people worldwide. Together, we are working to shape the future of health through differentiated products and services.

About DePuy Synthes
DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com .

*DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its affiliates.
**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and cardiovascular businesses within Johnson & Johnson's Medical Devices segment.
** * Mr Peter James is a paid consultant to DePuy Synthes Joint Reconstruction.
The third-party trademarks used herein are the trademarks of their respective owners.

©Johnson & Johnson Medical Limited. 2018. All rights reserved.

Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the launch of a new product, the ATTUNE® Revision Knee System. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; product efficacy or safety concerns resulting in product recalls or regulatory action; manufacturing difficulties and delays; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including under the captions “Item 1A. Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements,” and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Neither the Johnson & Johnson Medical Devices Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

1 14th Annual Report 2017: National Joint Registry for England, Wales, Northern Ireland and the Isle of Man, Surgical Data to 31 December 2016. Available online: http://www.njrreports.org.uk Accessed May 2018
van Loon C,Meermans G, Baas N, Vergroesen D, van Kampen P, Dwyer K, Lesko J, Huey V.Early Recovery Rate After A New Design Total Knee Arthroplasty (TKA): A Prospective, Multicenter Cohort of 200 Cases. Poster Accepted to World Arthroplasty Congress May 19-21, 2018. Rome, Italy, Poster # P101.

© DePuy Synthes 2018. All rights reserved.


Filed under: Tagged:
Results per page: 
Back To Top